NO20050807L - Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser - Google Patents

Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser

Info

Publication number: NO20050807L
Authority: NO; Norway
Prior art keywords: quinidine; pharmaceutical compositions; neurological disorders; treatment; compositions including
Prior art date: 2002-07-17

Application number

NO20050807A

Other languages

English (en)

Other versions

NO330626B1 (no

Inventor

Laura E Pope

Gerald Yakatan

James Berg

Richard A Smith

Original Assignee

Avanir Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-17

Filing date

2005-02-15

Publication date

2005-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30116047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050807(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-15 Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc

2005-02-15 Publication of NO20050807L publication Critical patent/NO20050807L/no

2011-05-30 Publication of NO330626B1 publication Critical patent/NO330626B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Other In-Based Heterocyclic Compounds (AREA)

NO20050807A 2002-07-17 2005-02-15 Farmasoytiske sammensetninger som innbefatter dekstrometorfan og quinidin for behandling av neurologiske forstyrrelser NO330626B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39666102P	2002-07-17	2002-07-17
PCT/US2003/022303 WO2004006930A1 (en)	2002-07-17	2003-07-17	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Publications (2)

Publication Number	Publication Date
NO20050807L true NO20050807L (no)	2005-02-15
NO330626B1 NO330626B1 (no)	2011-05-30

Family

ID=30116047

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20050807A NO330626B1 (no)	2002-07-17	2005-02-15	Farmasoytiske sammensetninger som innbefatter dekstrometorfan og quinidin for behandling av neurologiske forstyrrelser
NO2013017C NO2013017I2 (no)	2002-07-17	2013-11-21	(a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2013017C NO2013017I2 (no)	2002-07-17	2013-11-21	(a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat

Country Status (23)

Country	Link
US (12)	US7659282B2 (no)
EP (6)	EP2322179A1 (no)
JP (12)	JP5082032B2 (no)
KR (7)	KR20160055963A (no)
AT (1)	ATE399553T1 (no)
AU (3)	AU2003251971B9 (no)
BE (1)	BE2013C064I2 (no)
CA (1)	CA2492081C (no)
CY (2)	CY1110405T1 (no)
DE (1)	DE60321929D1 (no)
DK (2)	DK1539166T3 (no)
ES (2)	ES2309351T3 (no)
FR (1)	FR13C0062I2 (no)
HU (2)	HUE028100T2 (no)
IL (7)	IL166166A0 (no)
LU (1)	LU92323I2 (no)
NO (2)	NO330626B1 (no)
PL (2)	PL213552B1 (no)
PT (2)	PT1980252E (no)
RU (1)	RU2341265C2 (no)
SI (2)	SI1980252T1 (no)
TW (1)	TWI326214B (no)
WO (1)	WO2004006930A1 (no)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3405058B2 (ja)	1996-03-29	2003-05-12	スズキ株式会社	トランスファの潤滑構造
TWI326214B (en) *	2002-07-17	2010-06-21	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7754767B2 (en) *	2002-11-06	2010-07-13	Trinity Laboratories, Inc.	Method for treatment of premature ejaculation in humans
JP2007530664A (ja) *	2004-03-30	2007-11-01	ペインセプターファーマコーポレーション	ゲートイオンチャンネルを調節するための組成物及び方法
US20070191411A1 (en) *	2004-10-07	2007-08-16	Smith Richard A	Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US20060205822A1 (en) *	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
KR20080097443A (ko) *	2006-02-03	2008-11-05	아바니르 파마슈티컬스	덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
US20160143901A1 (en) *	2006-02-03	2016-05-26	Avanir Pharmaceuticals, Inc.	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
MX341177B (es)	2007-05-01	2016-08-10	Concert Pharmaceuticals Inc	Compuestos de morfina.
AU2008247818B2 (en)	2007-05-01	2011-10-20	Sun Pharmaceutical Industries, Inc.	Morphinan compounds
SI2792662T1 (sl)	2007-05-01	2016-10-28	Concert Pharmacuticals Inc.	Spojine morfinana
WO2009006194A1 (en) *	2007-06-28	2009-01-08	Avanir Pharmaceuticals	Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
DK2418211T3 (en)	2008-09-19	2016-06-27	Concert Pharmaceuticals Inc	DEUTERATED MORPHINAN COMPOUNDS
WO2011014003A2 (en) *	2009-07-29	2011-02-03	Green Cross Corporation	(+)-3-hydroxymorphinan derivatives as neuroprotectants
CA2712848A1 (en) *	2009-08-28	2011-02-28	Avanir Pharmaceuticals, Inc.	A method of reducing cns and gastrointestinal side affects associated with long-term, dextromethorphan/low-dose quinidine combination therapy
EP2566478A4 (en) *	2010-05-03	2014-04-30	Tsh Biopharm Corp Ltd	PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION
US8822471B2 (en) *	2011-03-14	2014-09-02	Boehringer Ingelheim International Gmbh	Compounds, pharmaceutical compositions and uses thereof
US8569328B1 (en) *	2011-05-24	2013-10-29	Antecip Bioventures Ii Llc	Compositions and methods comprising tilidine or related compounds and dextromethorphan
JP6094578B2 (ja)	2011-06-09	2017-03-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
US20130274282A1 (en) *	2012-04-16	2013-10-17	Herriot Tabuteau	Compositions and methods comprising celecoxib or related compounds and dextromethorphan
US10835495B2 (en)	2012-11-14	2020-11-17	W. R. Grace & Co.-Conn.	Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
AU2014225422A1 (en) *	2013-03-07	2015-10-15	Mindlab LLC	Pain medicine combination and uses thereof
US11524007B2 (en)	2013-11-05	2022-12-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10966974B2 (en)	2013-11-05	2021-04-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11576909B2 (en)	2013-11-05	2023-02-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10512643B2 (en) *	2013-11-05	2019-12-24	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10945973B2 (en)	2013-11-05	2021-03-16	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9763932B2 (en)	2013-11-05	2017-09-19	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9402843B2 (en) *	2013-11-05	2016-08-02	Antecip Bioventures Ii Llc	Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11541021B2 (en)	2013-11-05	2023-01-03	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11096937B2 (en)	2013-11-05	2021-08-24	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11197839B2 (en)	2013-11-05	2021-12-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10966941B2 (en)	2013-11-05	2021-04-06	Antecip Bioventures Ii Llp	Bupropion as a modulator of drug activity
US11534414B2 (en)	2013-11-05	2022-12-27	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11213521B2 (en)	2013-11-05	2022-01-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11129826B2 (en)	2013-11-05	2021-09-28	Axsome Therapeutics, Inc.	Bupropion as a modulator of drug activity
US11291665B2 (en)	2013-11-05	2022-04-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11426401B2 (en) *	2013-11-05	2022-08-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11510918B2 (en)	2013-11-05	2022-11-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11344544B2 (en)	2013-11-05	2022-05-31	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9408815B2 (en)	2013-11-05	2016-08-09	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10894047B2 (en)	2013-11-05	2021-01-19	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9867819B2 (en) *	2013-11-05	2018-01-16	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10688066B2 (en)	2018-03-20	2020-06-23	Antecip Bioventures Ii Llc	Bupropion and dextromethorphan for treating nicotine addiction
US20200338022A1 (en)	2019-01-07	2020-10-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9861595B2 (en)	2013-11-05	2018-01-09	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11541048B2 (en)	2013-11-05	2023-01-03	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11969421B2 (en)	2013-11-05	2024-04-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11147808B2 (en)	2013-11-05	2021-10-19	Antecip Bioventures Ii Llc	Method of decreasing the fluctuation index of dextromethorphan
US10786469B2 (en)	2013-11-05	2020-09-29	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9968568B2 (en)	2013-11-05	2018-05-15	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10894046B2 (en)	2013-11-05	2021-01-19	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11285146B2 (en)	2013-11-05	2022-03-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11571399B2 (en)	2013-11-05	2023-02-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11439636B1 (en) *	2013-11-05	2022-09-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11185515B2 (en)	2013-11-05	2021-11-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11298352B2 (en)	2013-11-05	2022-04-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11123344B2 (en)	2013-11-05	2021-09-21	Axsome Therapeutics, Inc.	Bupropion as a modulator of drug activity
US10898453B2 (en)	2013-11-05	2021-01-26	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11617747B2 (en)	2013-11-05	2023-04-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11207281B2 (en)	2013-11-05	2021-12-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9700528B2 (en)	2013-11-05	2017-07-11	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9474731B1 (en)	2013-11-05	2016-10-25	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273134B2 (en)	2013-11-05	2022-03-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11020389B2 (en)	2013-11-05	2021-06-01	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11311534B2 (en)	2013-11-05	2022-04-26	Antecip Bio Ventures Ii Llc	Bupropion as a modulator of drug activity
US11596627B2 (en)	2013-11-05	2023-03-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20160324807A1 (en)	2013-11-05	2016-11-10	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11571417B2 (en)	2013-11-05	2023-02-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10105361B2 (en)	2013-11-05	2018-10-23	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10940124B2 (en)	2019-01-07	2021-03-09	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
MY179696A (en) *	2013-11-05	2020-11-11	Antecip Bioventures Ii Llc	Compositions and methods comprising bupropion or related compounds and dextromethorphan
US10080727B2 (en)	2013-11-05	2018-09-25	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9457025B2 (en)	2013-11-05	2016-10-04	Antecip Bioventures Ii Llc	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11234946B2 (en)	2013-11-05	2022-02-01	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11357744B2 (en)	2013-11-05	2022-06-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US12194006B2 (en)	2013-11-05	2025-01-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11285118B2 (en)	2013-11-05	2022-03-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11229640B2 (en)	2013-11-05	2022-01-25	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
US11590124B2 (en)	2013-11-05	2023-02-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11419867B2 (en)	2013-11-05	2022-08-23	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US12109178B2 (en)	2013-11-05	2024-10-08	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10933034B2 (en)	2013-11-05	2021-03-02	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9707191B2 (en)	2013-11-05	2017-07-18	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11191739B2 (en)	2013-11-05	2021-12-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11058648B2 (en)	2013-11-05	2021-07-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11007189B2 (en)	2013-11-05	2021-05-18	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10874663B2 (en)	2013-11-05	2020-12-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11576877B2 (en)	2013-11-05	2023-02-14	Antecip Bioventures Ii Llc	Bupropion as modulator of drug activity
US20200261431A1 (en)	2019-01-07	2020-08-20	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11141416B2 (en)	2013-11-05	2021-10-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10874664B2 (en)	2013-11-05	2020-12-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11123343B2 (en)	2013-11-05	2021-09-21	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9198905B2 (en) *	2013-11-05	2015-12-01	Antecip Bioventures Ii Llc	Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US11382874B2 (en)	2013-11-05	2022-07-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10864209B2 (en)	2013-11-05	2020-12-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20220233470A1 (en)	2013-11-05	2022-07-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10881657B2 (en)	2013-11-05	2021-01-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10874665B2 (en)	2013-11-05	2020-12-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11517543B2 (en)	2013-11-05	2022-12-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11497721B2 (en)	2013-11-05	2022-11-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11253491B2 (en)	2013-11-05	2022-02-22	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11298351B2 (en)	2013-11-05	2022-04-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11273133B2 (en)	2013-11-05	2022-03-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11364233B2 (en)	2013-11-05	2022-06-21	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11253492B2 (en)	2013-11-05	2022-02-22	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10799497B2 (en)	2013-11-05	2020-10-13	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
US11065248B2 (en)	2013-11-05	2021-07-20	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10813924B2 (en)	2018-03-20	2020-10-27	Antecip Bioventures Ii Llc	Bupropion and dextromethorphan for treating nicotine addiction
US11433067B2 (en)	2013-11-05	2022-09-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20160361305A1 (en) *	2013-11-05	2016-12-15	Antecip Bioventures Ii Llc	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US10966942B2 (en)	2019-01-07	2021-04-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11426370B2 (en)	2013-11-05	2022-08-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11478468B2 (en)	2013-11-05	2022-10-25	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10772850B2 (en)	2013-11-05	2020-09-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10980800B2 (en)	2013-11-05	2021-04-20	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11291638B2 (en)	2013-11-05	2022-04-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10105327B2 (en)	2013-11-05	2018-10-23	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US9457023B1 (en)	2013-11-05	2016-10-04	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11617728B2 (en)	2013-11-05	2023-04-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11090300B2 (en)	2013-11-05	2021-08-17	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
CN107072990A (zh) *	2014-09-14	2017-08-18	阿瓦尼尔制药股份有限公司	用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
WO2016109679A1 (en) *	2014-12-31	2016-07-07	Markovitz M D Ph D Paul	Method of treating schizophrenia
CA2994157A1 (en) *	2015-07-30	2017-02-02	Concert Pharmaceuticals, Inc.	Morphinan compounds for treating agitation
WO2017117347A1 (en) *	2015-12-30	2017-07-06	Markovitz M D Paul	Method of treating schizophrenia
JP7061079B2 (ja)	2016-07-04	2022-04-27	アヴェニールファーマシューティカルズ，インコーポレイテッド	重水素化デキストロメトルファンの合成方法
US10888552B2 (en)	2016-08-12	2021-01-12	Steven Rothman	Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
BR112019003811A2 (pt) *	2016-08-26	2019-05-21	Exciva Ug (Haftungsbeschränkt)	composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição
WO2018052926A1 (en)	2016-09-13	2018-03-22	Mindlab LLC	Medicine combinations and treatment of restless leg syndrome
US11478467B2 (en)	2017-05-04	2022-10-25	Sreenivasarao Vepachedu	Targeted drug rescue with novel compositions, combinations, and methods thereof
WO2018204713A1 (en)	2017-05-04	2018-11-08	Exciva Ug (Haftungsbeschränkt)	Targeted drug rescue with novel compositions, combinations, and methods thereof
TWI795446B (zh)	2017-10-04	2023-03-11	美商神經治療股份有限公司	右旋美索芬(dextromethorphan)經皮輸送裝置
US10925842B2 (en)	2019-01-07	2021-02-23	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
JP2022526101A (ja) *	2019-03-18	2022-05-23	アヴェニールファーマシューティカルズ，インコーポレイテッド	重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
CN114469882B (zh) *	2022-04-06	2023-10-20	北京剂泰医药科技有限公司	一种右美沙芬奎尼丁口崩片及其应用
CN114569742B (zh) *	2022-05-09	2022-07-19	北京剂泰医药科技有限公司	一种组合物及其制备方法和应用
US11717518B1 (en)	2022-06-30	2023-08-08	Antecip Bioventures Ii Llc	Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en)	2022-07-07	2023-08-22	Antecip Bioventures Ii Llc	Treatment of depression in certain patient populations
EP4590292A1 (en)	2022-09-21	2025-07-30	Axsome Therapeutics, Inc.	Compounds and combinations thereof for treating neurological and psychiatric conditions
CN117797103A (zh) *	2023-12-11	2024-04-02	杭州剂泰医药科技有限责任公司	包装的右美沙芬奎尼丁口崩片

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5A (en) *		1836-08-10	Thomas Blanchard	Machine for mortising solid wooden shells of ships' tackle-blocks
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4316888A (en) *	1980-04-15	1982-02-23	Nelson Research & Development Co.	Method and composition of reducing pain
US4806543A (en)	1986-11-25	1989-02-21	Board Of Trustees Of The Leland Stanford Junior University	Method and compositions for reducing neurotoxic injury
US5034400A (en)	1989-10-20	1991-07-23	Olney John W	Method for preventing neurotoxic side effects of NMDA antagonists
JP2893866B2 (ja) *	1990-05-25	1999-05-24	日本油脂株式会社	抗不整脈薬
US5366980A (en)	1991-06-17	1994-11-22	Smith Richard A	Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en)	1991-06-17	1994-09-27	Smith Richard A	Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5206248A (en) *	1992-03-27	1993-04-27	Smith Richard A	Method for reducing emotional lability
US5166207A (en)	1991-06-17	1992-11-24	Neurotherapeutics, Inc.	Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
PL174373B1 (pl) *	1992-08-03	1998-07-31	Sepracor Inc	Środek farmaceutyczny zawierający metabolit terfenadyny
US5321012A (en) *	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) *	1993-03-05	2005-11-01	David J. Mayer	Method for the treatment of pain
US5352683A (en) *	1993-03-05	1994-10-04	Virginia Commonwealth University Medical College Of Virginia	Method for the treatment of chronic pain
AU8071894A (en) *	1994-09-22	1996-04-09	Jonathan M Licht	Compositions useful for the preparation of medicines for treating a variety of intractable disorders
EP1125935A3 (en) *	1995-08-03	2001-12-12	Dade Behring Inc.	Quinidine conjugates and their use in immunoassays
WO2000017366A2 (en)	1998-09-21	2000-03-30	Transgene S.A.	Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
CN1479628A (zh) *	1999-04-07	2004-03-03	�Ʒ�	Cyp2d6抑制剂在联合治疗中的用途
US6207674B1 (en) *	1999-12-22	2001-03-27	Richard A. Smith	Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6924273B2 (en)	2000-10-03	2005-08-02	Scott W. Pierce	Chondroprotective/restorative compositions and methods of use thereof
US20040087479A1 (en)	2001-04-30	2004-05-06	Sosnowski Robert E.	Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
TWI326214B (en) *	2002-07-17	2010-06-21	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR20080097443A (ko) *	2006-02-03	2008-11-05	아바니르 파마슈티컬스	덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
KR101590378B1 (ko) *	2009-09-07	2016-02-02	에스케이텔레콤 주식회사	근거리 영역 내의 방송통신 융합 구간에 대한 신호 간섭 최소화 시스템 및 방법, 그리고 이에 적용되는 장치

2003
- 2003-07-15 TW TW092119228A patent/TWI326214B/zh not_active IP Right Cessation
- 2003-07-17 EP EP10185871A patent/EP2322179A1/en not_active Withdrawn
- 2003-07-17 EP EP17170411.7A patent/EP3281630A1/en not_active Withdrawn
- 2003-07-17 KR KR1020167011631A patent/KR20160055963A/ko not_active Ceased
- 2003-07-17 SI SI200332454T patent/SI1980252T1/sl unknown
- 2003-07-17 AU AU2003251971A patent/AU2003251971B9/en not_active Expired
- 2003-07-17 CA CA2492081A patent/CA2492081C/en not_active Expired - Lifetime
- 2003-07-17 KR KR1020137005412A patent/KR101622446B1/ko not_active Expired - Lifetime
- 2003-07-17 ES ES03764769T patent/ES2309351T3/es not_active Expired - Lifetime
- 2003-07-17 KR KR1020127011436A patent/KR20120089706A/ko not_active Ceased
- 2003-07-17 KR KR1020137005416A patent/KR101588095B1/ko not_active Expired - Lifetime
- 2003-07-17 RU RU2005104418/14A patent/RU2341265C2/ru active
- 2003-07-17 HU HUE08154443A patent/HUE028100T2/en unknown
- 2003-07-17 AT AT03764769T patent/ATE399553T1/de active
- 2003-07-17 EP EP03764769A patent/EP1539166B1/en not_active Expired - Lifetime
- 2003-07-17 DK DK03764769T patent/DK1539166T3/da active
- 2003-07-17 PT PT81544439T patent/PT1980252E/pt unknown
- 2003-07-17 KR KR1020197037633A patent/KR20190143466A/ko not_active Ceased
- 2003-07-17 PT PT03764769T patent/PT1539166E/pt unknown
- 2003-07-17 KR KR1020117000825A patent/KR20110010669A/ko not_active Ceased
- 2003-07-17 EP EP20201438.7A patent/EP3824889A1/en not_active Withdrawn
- 2003-07-17 JP JP2004521935A patent/JP5082032B2/ja not_active Expired - Lifetime
- 2003-07-17 PL PL374026A patent/PL213552B1/pl unknown
- 2003-07-17 SI SI200331353T patent/SI1539166T1/sl unknown
- 2003-07-17 EP EP08154443.9A patent/EP1980252B1/en not_active Expired - Lifetime
- 2003-07-17 DE DE60321929T patent/DE60321929D1/de not_active Expired - Lifetime
- 2003-07-17 ES ES08154443.9T patent/ES2553654T3/es not_active Expired - Lifetime
- 2003-07-17 KR KR1020057001114A patent/KR20050043893A/ko not_active Ceased
- 2003-07-17 EP EP18188054.3A patent/EP3459547A1/en not_active Withdrawn
- 2003-07-17 DK DK08154443.9T patent/DK1980252T3/en active
- 2003-07-17 WO PCT/US2003/022303 patent/WO2004006930A1/en active Application Filing
- 2003-07-17 PL PL398445A patent/PL398445A1/pl unknown
2005
- 2005-01-05 IL IL16616605A patent/IL166166A0/xx unknown
- 2005-01-12 US US11/035,213 patent/US7659282B2/en active Active
- 2005-02-15 NO NO20050807A patent/NO330626B1/no not_active IP Right Cessation
2008
- 2008-04-22 AU AU2008201775A patent/AU2008201775B2/en not_active Expired
- 2008-09-30 CY CY20081101086T patent/CY1110405T1/el unknown
- 2008-11-25 US US12/323,214 patent/US20090082384A1/en not_active Abandoned
2010
- 2010-02-03 US US12/699,408 patent/US20100137352A1/en not_active Abandoned
- 2010-08-13 AU AU2010212348A patent/AU2010212348B2/en not_active Expired
2011
- 2011-03-06 IL IL211593A patent/IL211593A0/en unknown
- 2011-07-15 JP JP2011157054A patent/JP2011225601A/ja active Pending
2012
- 2012-02-07 JP JP2012024387A patent/JP2012116858A/ja active Pending
- 2012-03-08 US US13/415,067 patent/US8227484B2/en not_active Expired - Fee Related
- 2012-11-16 US US13/679,256 patent/US20130072517A1/en not_active Abandoned
2013
- 2013-03-13 IL IL225192A patent/IL225192A/en active IP Right Grant
- 2013-03-13 IL IL225191A patent/IL225191A/en active IP Right Grant
- 2013-03-13 IL IL225190A patent/IL225190A/en active IP Right Grant
- 2013-10-21 US US14/059,058 patent/US20140045880A1/en not_active Abandoned
- 2013-11-08 CY CY2013041C patent/CY2013041I1/el unknown
- 2013-11-14 HU HUS1300069C patent/HUS1300069I1/hu unknown
- 2013-11-20 BE BE2013C064C patent/BE2013C064I2/fr unknown
- 2013-11-21 NO NO2013017C patent/NO2013017I2/no not_active IP Right Cessation
- 2013-11-22 FR FR13C0062C patent/FR13C0062I2/fr active Active
- 2013-12-04 LU LU92323C patent/LU92323I2/xx unknown
- 2013-12-27 JP JP2013272584A patent/JP2014058575A/ja active Pending
2014
- 2014-02-26 JP JP2014035209A patent/JP2014129384A/ja active Pending
- 2014-06-06 US US14/298,571 patent/US20140288114A1/en not_active Abandoned
2015
- 2015-04-07 US US14/680,275 patent/US20150209347A1/en not_active Abandoned
- 2015-09-16 JP JP2015182769A patent/JP6074000B2/ja not_active Expired - Lifetime
2016
- 2016-03-16 JP JP2016051838A patent/JP6097859B2/ja not_active Expired - Lifetime
- 2016-04-06 US US15/092,316 patent/US20160287576A1/en not_active Abandoned
- 2016-11-21 JP JP2016225766A patent/JP6332651B2/ja not_active Expired - Lifetime
2017
- 2017-02-17 JP JP2017027686A patent/JP2017088620A/ja active Pending
- 2017-05-22 US US15/601,150 patent/US20180098984A1/en not_active Abandoned
- 2017-12-03 IL IL256054A patent/IL256054A/en unknown
2018
- 2018-06-04 JP JP2018106910A patent/JP2018150368A/ja active Pending
- 2018-07-26 US US16/045,792 patent/US20190201391A1/en not_active Abandoned
2019
- 2019-06-16 IL IL267381A patent/IL267381A/en unknown
- 2019-10-03 US US16/591,879 patent/US20200276185A1/en not_active Abandoned
- 2019-10-21 JP JP2019191618A patent/JP2020063248A/ja active Pending
2021
- 2021-03-12 JP JP2021039908A patent/JP2021098743A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2017036337A (ja)	2017-02-16
CY1110405T1 (el)	2012-05-23
DK1980252T3 (en)	2015-11-30
US8227484B2 (en)	2012-07-24
US20100137352A1 (en)	2010-06-03
AU2003251971B2 (en)	2008-02-21
KR101622446B1 (ko)	2016-05-18
PL398445A1 (pl)	2012-06-04
KR20130043217A (ko)	2013-04-29
HUS1300069I1 (hu)	2016-10-28
JP5082032B2 (ja)	2012-11-28
AU2003251971A1 (en)	2004-02-02
JP6074000B2 (ja)	2017-02-01
TWI326214B (en)	2010-06-21
TW200403997A (en)	2004-03-16
EP3459547A1 (en)	2019-03-27
EP2322179A1 (en)	2011-05-18
NO2013017I1 (no)	2014-06-02
EP1980252B1 (en)	2015-08-19
US7659282B2 (en)	2010-02-09
KR101588095B1 (ko)	2016-01-25
JP6097859B2 (ja)	2017-03-15
EP1539166B1 (en)	2008-07-02
WO2004006930A1 (en)	2004-01-22
RU2005104418A (ru)	2005-10-27
AU2008201775A1 (en)	2008-05-15
US20140045880A1 (en)	2014-02-13
US20090082384A1 (en)	2009-03-26
EP1539166A1 (en)	2005-06-15
HK1076052A1 (en)	2006-01-06
US20200276185A1 (en)	2020-09-03
CA2492081C (en)	2010-09-07
JP2017088620A (ja)	2017-05-25
US20150209347A1 (en)	2015-07-30
KR20050043893A (ko)	2005-05-11
US20140288114A1 (en)	2014-09-25
IL211593A0 (en)	2011-05-31
EP3281630A1 (en)	2018-02-14
US20160287576A1 (en)	2016-10-06
NO330626B1 (no)	2011-05-30
JP2014129384A (ja)	2014-07-10
KR20110010669A (ko)	2011-02-01
JP2021098743A (ja)	2021-07-01
EP1980252A3 (en)	2008-12-24
CA2492081A1 (en)	2004-01-22
HUE028100T2 (en)	2016-11-28
IL225191A (en)	2017-03-30
EP1980252A2 (en)	2008-10-15
JP2020063248A (ja)	2020-04-23
IL225192A (en)	2017-12-31
CY2013041I2 (el)	2015-12-09
JP2016106150A (ja)	2016-06-16
JP2014058575A (ja)	2014-04-03
ES2309351T3 (es)	2008-12-16
IL225191A0 (en)	2013-06-27
DE60321929D1 (de)	2008-08-14
US20190201391A1 (en)	2019-07-04
IL267381A (en)	2019-08-29
BE2013C064I2 (no)	2022-08-09
PL213552B1 (pl)	2013-03-29
CY2013041I1 (el)	2015-12-09
KR20130041296A (ko)	2013-04-24
AU2010212348B2 (en)	2013-05-09
DK1539166T3 (da)	2008-10-20
PL374026A1 (en)	2005-09-19
KR20190143466A (ko)	2019-12-30
IL256054A (en)	2018-01-31
JP2018150368A (ja)	2018-09-27
US20050203125A1 (en)	2005-09-15
AU2008201775B2 (en)	2010-05-20
EP3824889A1 (en)	2021-05-26
IL166166A0 (en)	2006-01-15
PT1980252E (pt)	2015-12-01
AU2003251971B9 (en)	2008-04-24
PT1539166E (pt)	2008-10-14
ATE399553T1 (de)	2008-07-15
KR20120089706A (ko)	2012-08-13
LU92323I2 (fr)	2015-09-22
HK1123741A1 (en)	2009-06-26
US20130072517A1 (en)	2013-03-21
SI1980252T1 (sl)	2016-01-29
US20120165363A1 (en)	2012-06-28
KR20160055963A (ko)	2016-05-18
JP2011225601A (ja)	2011-11-10
US20180098984A1 (en)	2018-04-12
AU2010212348A1 (en)	2010-09-09
SI1539166T1 (sl)	2008-12-31
JP2016011304A (ja)	2016-01-21
JP2005537268A (ja)	2005-12-08
IL225190A (en)	2017-03-30
JP2012116858A (ja)	2012-06-21
ES2553654T3 (es)	2015-12-10
RU2341265C2 (ru)	2008-12-20
FR13C0062I1 (no)	2014-01-03
NO2013017I2 (no)	2015-09-07
JP6332651B2 (ja)	2018-05-30
FR13C0062I2 (fr)	2015-11-20

Publication	Publication Date	Title
NO20050807L (no)	2005-02-15	Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
CY1116464T1 (el)	2017-03-15	Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ATE512163T1 (de)	2011-06-15	Verabreichung von mitteln zur behandlung von entzündungen
JO2373B1 (en)	2006-12-12	W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR0307508A (pt)	2004-12-07	Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DK1545537T3 (da)	2007-07-02	Alfa-7-nikotinreceptoragonister og statiner i kombination
IS6558A (is)	2002-09-20	Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
MXPA05012358A (es)	2006-02-02	Combinacion farmaceutica que comprende modafinilo y otra droga.
EP1503748A4 (en)	2009-10-21	DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
DK1244438T3 (da)	2004-02-23	Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
BG105984A (bg)	2002-04-30	Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
TW200501958A (en)	2005-01-16	A therapeutic agent for treating a behavioral disorder
HRP20050580A2 (en)	2006-08-31	Synergistic combination comprising roflumilast and (r,r)-formoterol
DE60318041D1 (de)	2008-01-24	Synergistische kombination eines opiatanalgetikums und eines nsaid
TW200500073A (en)	2005-01-01	Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
FR2812549B1 (fr)	2003-03-21	Associations dalfopristine/quinupristine avec le cefpirome
CY1117102T1 (el)	2017-04-05	Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
EP1878728A3 (en)	2008-01-30	Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders

Legal Events

Date	Code	Title	Description
2014-06-23	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: NUEDEXTA - DEKSTROMETORFAN/QUINIDIN; REG. NO/DATE: EU/1/13/833/001-003 20130703 Spc suppl protection certif: 2013017 Filing date: 20131121
2015-09-07	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: NUEDEXTA - DEKSTROMETORFAN/QUINIDIN; REG. NO/DATE: EU/1/13/833/001-003 2013.07.03; FIRST REG.NO/DATE: EU/1/13/833/001-003 2013.06.24 Spc suppl protection certif: 2013017 Filing date: 20131121 Extension date: 20280624
2023-08-14	MK1K	Patent expired

Date

Code

Title

Description

2014-06-23

SPCF

Filing of supplementary protection certificate

Free format text: PRODUCT NAME: NUEDEXTA - DEKSTROMETORFAN/QUINIDIN; REG. NO/DATE: EU/1/13/833/001-003 20130703

Spc suppl protection certif: 2013017

Filing date: 20131121

2015-09-07

SPCG

Granted supplementary protection certificate

Free format text: PRODUCT NAME: NUEDEXTA - DEKSTROMETORFAN/QUINIDIN; REG. NO/DATE: EU/1/13/833/001-003 2013.07.03; FIRST REG.NO/DATE: EU/1/13/833/001-003 2013.06.24